Abstract: The present invention provides a method for preventing the defect the in shape of via holes cased when an alumina mask is used for the dry etching of an interlayer insulator composed of an SiOC film in the dual damascene process in which via holes are formed prior to forming wiring trenches. That is, after forming an alumina mask on an interlayer insulator composed of a low-k SiOC film via a cap insulator, the cap insulator and the interlayer insulator are dry-etched with using a photoresist film as a mask to form via holes. Next, after removing the photoresist film, the inside of the via holes are cleaned by using dilute hydrofluoric acid solution to remove alumina residue. Thereafter, the cap insulator and the interlayer insulator are dry-etched with using the alumina mask as a mask to form wiring trenches.

Abstract: A method is used for producing nanoscale and microscale devices in a variety of materials, such as silicon dioxide patterned buried films. The method is inexpensive and reliable for making small scale mechanical, optical, or electrical devices and relies upon the implantation of ions into a substrate and subsequent annealing to form a stoichiometric film with the device geometry is defined by the implant energy and dose and so is not limited by the usual process parameters.

Abstract: In a method of forming a thin-film structure employed in a non-volatile semiconductor device, an oxide film is formed on a substrate. An upper nitride film is formed on the oxide film by nitrifying an upper portion of the oxide film through a plasma nitration process. A lower nitride film is formed between the substrate and the oxide film by nitrifying a lower portion of the oxide film through a thermal nitration process. A damage to the thin-film structure generated in the plasma nitration process may be at least partially cured in the thermal nitration process, and/or may be cured in a post-thermal treatment process.

Abstract: A method for manufacturing a semiconductor device, in which a substrate is disposed in a chamber and a fluorine-containing silicon oxide film is formed on the substrate using a plasma CVD process. The fluorine-containing silicon oxide film is formed such that the release of fluorine from this silicon oxide layer is suppressed. According to this semiconductor device manufacturing method, a stable semiconductor device can be provided such that the device includes a fluorine-containing silicon oxide film (FSG film) at which the release of fluorine is suppressed, and thus peeling does not occur.

Abstract: A metal oxide thin film may be obtained by providing a source gas and an oxidizer gas. The source gas may include a hydrolyzable metallic compound. The oxidizer gas may include a hydrate of a metal salt. The metal oxide thin film may be obtained by alternately feeding the source gas and the oxidizer gas into a reaction chamber in which a substrate is placed.

Abstract: A fabric is provided for use in safety apparel, including a first yarn type comprising at least about 60 percent modacylic fibers and a second yarn type comprising an intimate blend of anti-static fibers and other fibers selected from the group of fibers consisting of polyester, nylon, rayon, modacrylic, cotton, wool, and combinations thereof. The fabric meets the American Society for Testing and Materials standard ASTM F-1506 for flame resistance, Federal Test Method Standard 191A, Method 5931 for electrostatic decay, and the Electrostatic Discharge Association Advisory ADV11.2-1995 voltage potential.

Abstract: An optical glass comprising in mass %: P2O5 25%-less than 45% B2O3 6-20% BaO 24%-less than 40% ZnO 3-14% MgO 0-15% CaO 0-15% SrO 0-15% Li2O 0-5% Na2O 0-5% K2O 0-5% WO3 0-5% and Al2O3 0-5%. The optical glass should preferably contain 0.1-5% WO3, 3.6-15% MgO, 0.1-5% Li2O+Na2O+K2O, 0—less than 0.5% and Sb2O3+As2O3 with the mass ratio of ZnO/BaO being 0.12—less than 0.50. The optical glass should preferably have refractive index (nd) within a range from 1.54 to 1.65 and Abbe number (?d) within a range exceeding 57 up to 69 and liquid phase temperature within a range from 870° C. to 930° C. There is provided an optical glass having high resistance to devitrification and medium refractive index and low dispersion characteristics which is free of ingredients such as Ta2O5 having a high cost of raw material and therefore can be manufactured at a relatively low cost of raw materials.

Abstract: It is to provide a silica glass containing TiO2, having a wide temperature range wherein the coefficient of thermal expansion is substantially zero. A silica glass containing TiO2, which has a TiO2 concentration of from 3 to 10 mass %, a OH group concentration of at most 600 mass ppm and a Ti3+ concentration of at most 70 mass ppm, characterized by having a fictive temperature of at most 1,200° C., a coefficient of thermal expansion from 0 to 100° C. of 0±150 ppb/° C., and an internal transmittance T400-700 per 1 mm thickness in a wavelength range of from 400 to 700 nm of at least 80%. A process for producing a silica glass containing TiO2, which comprises porous glass body formation step, F-doping step, oxygen treatment step, densification step and vitrification step.

Abstract: A sintered ceramic composition includes at least 50 wt. % boron carbide and at least 0.01 wt. % of at least one element selected from the group consisting of Y, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy Ho, Er, Tm, Yb, and Lu, the sintered ceramic composition being characterized by a density of at least 90% of theoretical density.

Abstract: Disclosed are sintered bodies that include: (a) 30 to 100 mol % of NbOx, wherein 0.5<x<1.5; and (b) 0 to 70 mol % of MgO. The sintered bodies may be used as inert apparatuses in the production of niobium suboxide powder or niobium suboxide anodes, or as chemically resistant components in chemical apparatuses.

Abstract: A ceramic electronic device including a dielectric layer, wherein the dielectric layer includes a main component expressed by a composition formula of Bam TiO2+m, wherein “m” satisfies 0.995?m?1.010 and a ratio of Ba and Ti satisfies 0.995?Ba/Ti?1.010, and a subcomponent (a sixth subcomponent) including an oxide of Al; and a content of the Al compound is 0 to 4.0 moles (note that 0 is not included) in terms of Al2O3 with respect to 100 moles of the main component; and preferably, the dielectric layer includes a segregation phase, and the segregation phase includes an oxide of Al.

Abstract: A process for enhancing the activity of a catalyst metal particulate for hydrogenation reactions comprising calcining the particulate in an oxidant-containing atmosphere to partially oxidize it thereby forming a porous layer of oxides thereon, treating with an solution capable of oxidizing the calcined metal particulate and comprising a compound of a hydrogenation catalyst metal to where said metal particulate has absorbed a volume of solution equal to at least about 10% of its calculated pore volume and activating it by treatment with a hydrogen-containing gas at elevated temperatures thereby forming a dispersed active metal catalyst. Preferably, the treated particulate is calcined a second time under the same conditions as the first before final activation with a hydrogen-containing gas. The metal particulate is preferably sized after each calcination and any agglomerates larger than 250 microns are comminuted to a desired size.

Abstract: A process for the production of ethylbenzene by the ethylation of benzene in the critical phase over a molecular sieve aromatic alkylation catalyst comprising cerium-promoted zeolite beta. An aromatic feedstock having a benzene content of at least 90 wt. % is supplied into a reaction zone and into contact with the cerium-promoted zeolite beta having a silica/alumina mole ratio within the range of 50-150 and a cerium-aluminum ratio of 0.5-1.5. Ethylene is supplied to the alkylation reaction zone in an amount to provide a benzene/ethylene mole ratio of 1-15. The reaction zone is operated at temperature and pressure conditions in which benzene is in the super critical phase to cause ethylation of the benzene in the presence of the cerium zeolite beta alkylation catalyst. An alkylation product is produced containing ethylbenzene as a primary product with the attendant production of heavier alkylated by-products of no more than 60 wt. % of the ethylbenzene.

Abstract: The present invention regards a catalytic composition comprising gallium, at least one element chosen in the group of the lanthanides, and a zeolite belonging to the MFI, MEL or MFI/MEL families, the crystal lattice of which is made up of silicon oxide and at least one metal oxide chosen from among aluminum oxide, boron oxide and gallium oxide. Preferably, in the catalytic compositions of the present invention a zeolite is used belonging to the MFI family characterized by crystallites which for at least 90% have diameters smaller than 500 ? and which can form agglomerates of submicron dimensions characterized by possessing at least 30% of the extrazeolitic porosity in the region of the mesopores. The catalytic compositions of the present invention can, in addition, contain rhenium. These catalytic compositions are useful in processes of aromatization of hydrocarbons containing from 3 to 6 carbon atoms, preferably, hydrocarbon mixtures containing olefins.

Abstract: A catalyst is described which comprises at least one zeolite with channels with openings defined by a ring having 10 oxygen atoms (10 MI), at least one zeolite with at least channels or side pockets with openings defined by a ring having 12 oxygen atoms (12 MR), at least one metal selected from the group constituted by group IIIA and VIIB metals and at least one porous mineral matrix. Said catalyst optionally also contains at least one metal selected from the group constituted by group IVA and VIB metals. The catalyst of the invention is used in a process for the transalkylation of alkylaromatic hydrocarbons such as toluene or benzene and alkylaromatics containing at least 9 carbon atoms.

Abstract: The method for preserving a catalyst of the present invention is characterized in that, in a process for continuously producing an objective product by a vapor phase oxidation reaction using a phosphorus-molybdenum-vanadium catalyst containing phosphorus, molybdenum and vanadium, the phosphorus-molybdenum-vanadium catalyst retained in a reactor is maintained under a condition of a water content of 30 mg or less per 1 g of catalyst dry weight, before the start of the reaction or during the stop of the reaction. By this, deterioration of the catalyst retained in the reactor can be simply prevented.

Abstract: A practical chiral zirconium catalyst that can maintain its high catalytic activity even after long-term storage, which is stable in air and storable for a long period of time, and recoverable and reusable after reaction, is provided.

Abstract: A reversible thermosensitive coloring material which can reversibly achieve a relatively colored state and a relatively discolored state depending on a temperature to which the coloring material is heated or a cooling speed at which the coloring material is cooled after heated. The coloring material including an electron donating coloring agent; an electron accepting color developer configured to color the coloring agent; and a compound having a Zwitter ion in which a total of charges in a molecule of the compound is zero. A reversible thermosensitive recording material including a substrate and a reversible thermosensitive recording layer, which is located overlying the substrate and which includes the reversible thermosensitive coloring material.

Abstract: A heat-sensitive recording material comprising on one surface of a substrate a heat-sensitive coloring layer comprising a leuco dye and a color developer, wherein the heat-sensitive recording material comprises a layer which comprises a copolymer of a (meth)acryloyloxyalkylammonium salt and styrene; and the layer which comprises the copolymer of the (meth)acryloyloxyalkylammonium salt and styrene is at least any one of a back layer, an under layer and a protective layer.

Abstract: Novel optically active ?1-pyrrolines of the formula (I) in which R1, R2, R3, R4, and m are each as defined in the description, a plurality of the processes for preparing these substances and their use for controlling pests.

Abstract: A method of delivering chemicals such as scale inhibitor into a wellbore producing fluids includes providing the chemicals, in a slow-release form, in a container located in the path of the production fluids so that the production fluids pass through the container. Preferably, the container is suspended in the production tubing and periodically retrieved from the well to be refilled.

Abstract: A method of treating a subterranean formation, the method comprising: (A) injecting down a well bore into the formation an admixture of (a) an emulsion having an internal aqueous phase comprising a water-soluble oil or gas field chemical or an aqueous dispersion of a water-dispersible oil or gas field chemical and an external oil phase comprising a liquid hydrocarbon and an oil-soluble surfactant and (b) a demulsifier comprising a solution of a surfactant having a cloud point temperature of above 40° C.; or (B) separately injecting down a well bore into the formation emulsion (a) and demulsifier (b) and generating an admixture of emulsion (a) and demulsifier (b) within the formation.

Abstract: The invention describes a method for decreasing the viscosity of crude oils and residuum utilizing a combination of thermal and acidic treatment. Further, the invention describes a method for making a water-in-oil emulsion, or a solids-stabilized water-in-oil emulsion with a reduced viscosity. The emulsion can be used in enhanced oil recovery methods, including using the emulsion as a drive fluid to displace hydrocarbons in a subterranean formation, and using the emulsion as a barrier fluid for diverting flow of fluids in the formation.

Abstract: An engine lubricant that is substantially free of zinc and phosphorous contains an antiwear additive comprising borated 1,2 epoxy mixed polybutenes having an average carbon number in the range of C20 to about C120.

Abstract: Lubricant oil compositions containing a base oil and an additive package comprising one or more wear-resistant additives. The wear-resistant additives can be (a) a Group 1a alkali metal carbonate, a Group 2a alkaline earth metal carbonate, or a mixture thereof; (b) Group 1a alkali metal sulfate, a Group 2a alkaline earth metal sulfate, or a mixture thereof; (c) a Group 1a alkali metal phosphate, a Group 2a alkaline earth metal phosphate, or a mixture thereof; (d) Group 1a alkali metal carboxylate, a Group 2a alkaline earth metal carboxylate; or (e) a combination of (a), (b), (c), and (d). The wear-resistant additives are in the form of nanoparticles.

Abstract: The present invention relates to a lubricious anti-traction material for effectively denying the mobility and access of personnel and vehicles to selected areas. The anti-traction material is composed of a slurry combined with water. The slurry is composed of an emulsion or dispersion and an anionic acrylamide polymer.

Abstract: The use of novel methanoazulenofuran and methanoazulenone compounds for use as fragrance chemicals, suitable for use incorporated in a wide variety of products such as perfumes, colognes and personal care products having a structure wherein R is ?O, X is selected from the group consisting of H, CH3, C2H5, and CH2CH?CH2; or wherein R forms a fused ring with the ring carbon at the X position, X is absent; and Y and Z are selected from the group consisting of H and CH3.

Abstract: Compositions effective as disinfecting solutions for ophthalmic devices such as contact lenses are provided. The compositions include a microbicide, preferably polyhexamethylene biguanide or alexidine, and a water soluble salt of a bis-aminopolyol, preferably 1,3-bis(tris[hydroxymethyl]methylamino)propane, as a buffering agent.

Abstract: Cleaning compositions suitable for cleaning microelectronic structures having silicon dioxide, low-k or high-k dielectrics and copper or aluminum metallizations contain an oxidizing agent and a polar organic solvent selected from amides, sulfones, sulfolenes, selenones and saturated alcohols, and optionally other components.

Abstract: An apparatus for feeding slurry to an external device. The apparatus includes a preparation tank for preparing the slurry. A circulation pipe is connected to the preparation tank to circulate the slurry. A feeding pipe is connected between the preparation tank and the external device to feed the external device with the slurry. A pump sends the chemical solution in the preparation tank to the circulation pipe and the feeding pipe. A concentration detector is arranged downstream to the pump to detect the concentration of the slurry. A controller controls the concentration of the chemical solution in the preparation tank in accordance with the detection value of the concentration detector and controls the feeding of the chemical solution.

Abstract: The present invention relates to a granule comprising a core and a coating, wherein the core comprises an active compound, and the coating comprises filaments prepared from atomizing a liquid coating composition having the property that liquid coating composition forms filaments upon atomization.

Abstract: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that the foreign DNA is stably incorporated in the DNA of germ line cells of the mature animal. Particularly efficient expression was accomplished using a chimeric construct comprising a mammary gland specific promoter, Factor IX cDNA that lacked the complete or any portion of the 5?-untranslated and 3?-untranslated region, which is substituted with a 5-? and 3?-end of the mouse whey acidic protein gene. In vitro cell cultures of cells explanted from the transgenic mammal of the invention and methods of producing Factor IX from such said culture and methods of treating hemophilia B are also described.

Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of Factor VIIa or a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ?g/kg Factor VIIa or Factor VIIa equivalent.

Abstract: The invention provides a method of inhibiting ectopic calcification in an individual. The method consists of administering to the individual a therapeutically effective amount of osteopontin or a functional fragment thereof.

Abstract: Disclosed is a method of using synthetic analogs of natriuretic peptides and more particularly to synthetic linear peptide analogs as pro-lipolytic, as anti-obesity agents, and as intermediates for or modulators of such useful compounds. Inhibitors to nprC are disclosed to treat or prevent adipose accumulation in mammals.

Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Abstract: An isolated peptide useful as a selective antagonist of mammalian R-cadherin comprises 3 to 30 amino acid residues, three contiguous residues of the peptide having the amino acid sequence Ile-Xaa-Ser; wherein Xaa is an amino acid residue selected from the group consisting of Asp, Asn, Glu, and Gln. Preferably Xaa is Asp or Asn. In one preferred embodiment the peptide is a cyclic peptide having 3 to 10 amino acid residues arranged in a ring. The selective R-cadherin antagonist peptides of the invention are useful for inhibiting the targeting of stem cells, such as endothelial precursor cells, to developing vasculature, for inhibiting R-cadherin mediated cellular adhesion, and for inhibiting retinal angiogenesis.

Abstract: The present invention provides a cyclic peptide comprising the structure: wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, R is selected from the group consisting of oxygen, nitrogen, sulfur and carbon, n is 0 to 10 and y is 1 to 10. The present invention also provides a cyclic peptide comprising the amino acid sequence of NH2—X(n)-Z-X(y)—COOH and a cyclic bond between the Z residue and COOH other than a thioester bond, wherein X is selected from the group consisting of to an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, n is 0 to 10 and y is 1 to 10. Methods of preparation including a cyclization protocol, and methods of use of the cyclic peptides of the invention are also disclosed.

Abstract: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

Abstract: The present invention intends to provide a novel peptide and use thereof. More particularly, the present invention provides a novel peptide and a DNA encoding the same, a drug comprising the peptide or DNA, a screening method/screening kit for a compound or its salt that promotes or inhibits the activity of the peptide, a compound or its salt obtained by the screening, a drug comprising the compound or its salt, etc. The peptide of the invention and the DNA encoding the same are usable, e.g., for the diagnosis, treatment, prevention, etc. of digestive diseases, etc. Moreover, the peptide of the invention is useful as a reagent for screening a compound or its salt that promotes or inhibits the activity of the protein of the invention.

Abstract: Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically melanoma or metastatic melanoma, and use of the proteins and peptides as immunogens to inhibit, prevent or treat melanoma.

Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.

Abstract: D-pyranosyl-substituted phenyls of general formula I wherein the groups R1 to R5, X, Z and R7a, R7b, R7c are defined as in claim 1, have an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The present invention also relates to pharmaceutical compositions for the treatment of metabolic disorders.

Abstract: Two hitherto unreported novel hemiterpene glycosides were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of these hemiterpenes have been elucidated. These hemiterpene glycosides possess anti-platelet aggregation activity more potent than those of salvianolic acid B and aspirin and may be used in pharmaceutical compositions in humans and mammals in need of such treatment.

Abstract: Macrolides with anti-inflammatory activity are described. Particularly described are 9a-azalides and their anti-inflammatory activity without cladinose in position 3, the pharmaceutically acceptable salts thereof and the pharmaceutical composition that contain them as active principle.

Abstract: The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

Abstract: The present invention provides novel chemical compounds, and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivatives and related compounds as therapeutic agents to treat a number of conditions, including those associated with viral infection and cardiovascular diseases.

Abstract: A composition for treatment of HSV-related pathologies including an expression vector for altering expression of a target sequence in an HSV-infected cell by production of single-stranded cDNA (ssDNA) in the cell in vivo suspended for topical application to an affected site in a suitable delivery vehicle. The expression vector is comprised of a cassette comprising a sequence of interest, an inverted tandem repeat, and a primer binding site 3? to the inverted tandem repeat, and a reverse transcriptase/RNAse H coding gene, and is transfected into the infected cells for inhibition of HSV replication. The resulting ssDNA binds to the target sequence to alter expression of the target sequence for such purposes as gene activation or inactivation using duplex or triplex binding of nucleic acids, site-directed mutagenesis, interruption of cellular function by binding to specific cellular proteins, or interfering with RNA splicing functions.

Abstract: The subject of the present invention is specific lipidesters of halogenated nucleotides of the following formula wherein R1, R2, R3, X and Y are defined as described herein and salts thereof, said compounds have anti-cancer properties; pharmaceutical compositions containing the compounds, a method of synthesizing the compounds, and a method of using the compounds for treating malignant tumors.

Abstract: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2?,3?-dideoxy-2?,3?-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3?-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5? or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.